Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-07-17

Summary

Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.

The usefulness of carvedilol to prevent decompensation of cirrhosis in patients with TE-LSM ≥ 25 kPa as a surrogate marker for clinically significant portal hypertension, has never been evaluated in a clinical trial.

• Phase: PHASE3

Details

• Lead Sponsor: University Hospital, Tours
• Collaborators: Assistance Publique Hopitaux Paris AVICENNE; Assistance Publique Hopitaux Paris BEAUJON; Assistance Publique Hopitaux Paris HENRI MONDOR; Assistance Publique Hopitaux Paris LA PITIE SALPETRIERE; Assistance Publique Hopitaux Paris PAUL BROUSSE; Assistance Publique Hopitaux Paris ST ANTOINE; Centre Hospitalier intercommunal de Créteil; Centre Hospitalier Régional Universitaire Lille; Centre Hospitalier Universitaire Amiens Picardie; Centre Hospitalier Universitaire Angers; Centre Hospitalier Universitaire Caen; Centre Hospitalier Universitaire Clermont Ferrand; Centre Hospitalier Universitaire Dijon; Centre Hospitalier Universitaire Grenoble; Centre Hospitalier Universitaire Haut Lévêque; Centre Hospitalier Universitaire Jean Minjoz; Centre Hospitalier Universitaire Pontchaillou; Centre Hospitaliser Départemental de Vendée; CHU de Reims; Hôpitaux Universitaires de Strasbourg; Hospices Civils de Lyon; Nantes University Hospital; University Hospital, Montpellier; University Hospital, Toulouse
• Treatments: Carvedilol